跳至主要内容
临床试验/NL-OMON25190
NL-OMON25190招募中不适用

The effects of sex hormone administration on marrow and visceral adiposity

Amsterdam UMC, location VUmc0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ? Diagnosed with gender dysphoria according to DSM V (female-to-male or male-to-female)
  • ? Age between 18 and 50 years
  • ? Female-to-male transgenders need to be premenopausal
  • ? Starting cross-sex hormone treatment

排除标准

  • ? Previous use of cross-sex hormones
  • ? Contraindications to MRI scanning
  • ? Participation in other studies (with exception of the ENIGI study)
  • ? Use of bone-modifying or adipose tissue-modifying drugs, current or in history (bisphosphonates, estrogen receptor modulators, calcium regulating agents, corticosteroids)
  • ? Bone or bone marrow diseases, current or in history (metabolic, malignancy, infectious, mechanic, bone marrow diseases)
  • ? Platelet count <120*109/l
  • ? History of non-traumatic major bleeding
  • ? Known bleeding diathesis
  • ? Conditions which require antiplatelet therapy
  • ? Usage of antiplatelet therapy
  • ? Chronic usage of medication known to influence platelet function (e.g. DOAC’s, NSAIDs, warfarin)

研究者

发起方
Amsterdam UMC, location VUmc

相似试验